Damage and mortality in a group of British patients with systemic lupus erythematosus followed up for over 10 years

被引:195
作者
Chambers, Sharon A. [1 ]
Allen, Elizabeth [2 ]
Rahman, Anisur [1 ]
Isenberg, David [1 ]
机构
[1] UCL, Ctr Rheumatol, Dept Med, London, England
[2] London Sch Hyg & Trop Med, London WC1, England
关键词
Damage; Mortality; SLICC; ACR; SLE; Survival; Sepsis; Cancer; UK; Multiethnic; Musculoskeletal; SOCIOECONOMIC-STATUS; DISEASE-ACTIVITY; INDEX; PREDICTORS; MORBIDITY; DEATH; TIME;
D O I
10.1093/rheumatology/kep062
中图分类号
R5 [内科学];
学科分类号
100201 [内科学];
摘要
Objective. To study damage accrual and mortality in British patients with SLE under long-term follow-up for 10 years. Methods. We analysed the clinical records of 232 patients with SLE who had at least 10 years of consistent follow-up at University College London Hospital (UCLH). We noted their SLICC/ACR Damage Index (SDI) scores and category of damage at 1 year post-diagnosis of SLE and every 5 years thereafter. For patients who had died, we determined the year and cause of death. Results. Ninety per cent of patients had no damage at 1 year post-diagnosis of SLE; however by year 10, 50 had accrued some damage. Damage accrual was mostly in the neuropsychiatric, renal and musculoskeletal categories. An increase in damage score was associated with a higher risk of death overall. Forty-four patients died during the period of follow-up. Sepsis, cancer and organ failure (cardiac, renal and liver) were the main causes of death in this group of patients. Conclusions. Damage accrual is associated with an increased risk of mortality. Infections remain an important cause of death in patients with SLE.
引用
收藏
页码:673 / 675
页数:3
相关论文
共 20 条
[1]
Systemic lupus erythematosus in three ethnic groups.: XX.: Damage as a predictor of further damage [J].
Alarcón, GS ;
Roseman, JM ;
McGwin, G ;
Uribe, A ;
Bastian, HM ;
Fessler, BJ ;
Baethge, BA ;
Friedman, AW ;
Reveille, JD .
RHEUMATOLOGY, 2004, 43 (02) :202-205
[2]
Becker-Merok A, 2006, J RHEUMATOL, V33, P1570
[3]
Mortality in systemic lupus erythematosus [J].
Bernatsky, S. ;
Boivin, J. -F. ;
Joseph, L. ;
Manzi, S. ;
Ginzler, E. ;
Gladman, D. D. ;
Urowitz, M. ;
Fortin, P. R. ;
Petri, M. ;
Barr, S. ;
Gordon, C. ;
Bae, S. -C. ;
Isenberg, D. ;
Zoma, A. ;
Aranow, C. ;
Dooley, M. -A. ;
Nived, O. ;
Sturfelt, G. ;
Steinsson, K. ;
Alarcon, G. ;
Senecal, J. -L. ;
Zummer, M. ;
Hanly, J. ;
Ensworth, S. ;
Pope, J. ;
Edworthy, S. ;
Rahman, A. ;
Sibley, J. ;
El-Gabalawy, H. ;
McCarthy, T. ;
Pierre, Y. St. ;
Clarke, A. ;
Ramsey-Goldman, R. .
ARTHRITIS AND RHEUMATISM, 2006, 54 (08) :2550-2557
[4]
Bernatsky Sasha, 2005, Curr Rheumatol Rep, V7, P476
[5]
Can morbidity and mortality of SLE be improved? [J].
Bongu, A ;
Chang, E ;
Ramsey-Goldman, R .
BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY, 2002, 16 (02) :313-332
[6]
Morbidity and mortality in systemic lupus erythematosus during a 5-year period -: A multicenter prospective study of 1,000 patients [J].
Cervera, R ;
Khamashta, MA ;
Font, J ;
Sebastiani, GD ;
Gil, A ;
Lavilla, P ;
Aydintug, AO ;
Jedryka-Góral, A ;
de Ramón, E ;
Fernández-Nebro, A ;
Galeazzi, M ;
Haga, HJ ;
Mathieu, A ;
Houssiau, F ;
Ruiz-Irastorza, G ;
Ingelmo, M ;
Hughes, GRV .
MEDICINE, 1999, 78 (03) :167-175
[7]
GLADMAN D, 1992, J RHEUMATOL, V19, P1820
[8]
Gladman Dafna D., 1992, Current Opinion in Rheumatology, V4, P681
[9]
Gladman DD, 2003, J RHEUMATOL, V30, P1955
[10]
Jacobsen S, 1999, SCAND J RHEUMATOL, V28, P75